<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the efficacy and safety of Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation (BMT) with unrelated donor for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Six patients received chemotherapy regimen of <z:chebi fb="0" ids="28901">busulfan</z:chebi> (Bu) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) before allogeneic BMT (Bu 4 mg  </plain></SENT>
<SENT sid="2" pm="."><plain>kg(-1)  </plain></SENT>
<SENT sid="3" pm="."><plain>d(-1), -7 d - -4 d, CY 60 mg  </plain></SENT>
<SENT sid="4" pm="."><plain>kg(-1)  </plain></SENT>
<SENT sid="5" pm="."><plain>d(-1), -3 d - -2 d) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="168396">Mycophenolate</z:chebi> mofetil combined with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> was used for prevention of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> after transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>Lipo <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(1)was used in prophylactic regimen for <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">hepatic veno-occlusive disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULT: Neutrophil count began to be higher than 0.5 x 10(9)/Lat the 18th day after BMT </plain></SENT>
<SENT sid="9" pm="."><plain>Platelet count began to be higher than 20 x 10(9)/Lat the 21st day after BMT </plain></SENT>
<SENT sid="10" pm="."><plain>Disease-free survival in the six patients was 27 months </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation with unrelated donor is an effective therapy for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>